Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study
Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study
Bray, F, Ferlay, J, Soerjomataram, I, Siegel, RL, Torre, LA, Jemal, A, Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68 (2018), 394–424.
US National Cancer Institute. SEER cancer statistics review 1975–2015: cancer of the cervix uteri. https://seer.cancer.gov/archive/csr/1975_2015/results_merged/sect_05_cervix_uteri.pdf, Sept 10, 2018. (Accessed 22 March 2021)
Long, HJ 3rd, Bundy, BN, Grendys, EC Jr, et al. Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study. J Clin Oncol 23 (2005), 4626–4633.
Moore, DH, Blessing, JA, McQuellon, RP, et al. Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol 22 (2004), 3113–3119.
Monk, BJ, Sill, MW, McMeekin, DS, et al. Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 27 (2009), 4649–4655.
Tewari, KS, Sill, MW, Long, HJ 3rd, et al. Improved survival with bevacizumab in advanced cervical cancer. N Engl J Med 370 (2014), 734–743.
Kitagawa, R, Katsumata, N, Shibata, T, et al. Paclitaxel plus carboplatin versus paclitaxel plus cisplatin in metastatic or recurrent cervical cancer: the open-label randomized phase III trial JCOG0505. J Clin Oncol 33 (2015), 2129–2135.
Tewari, KS, Monk, BJ, Evidence-based treatment paradigms for management of invasive cervical carcinoma. J Clin Oncol 37 (2019), 2472–2489.
Marth, C, Landoni, F, Mahner, S, McCormack, M, Gonzalez-Martin, A, Colombo, N, Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 28:suppl 4 (2017), iv72–iv83.
Abu-Rustum, NR, Yashar, CM, Bean, S, et al. NCCN guidelines insights: cervical cancer, version 1.2020. J Natl Compr Canc Netw 18 (2020), 660–666.
Monk, BJ, Sill, MW, Burger, RA, Gray, HJ, Buekers, TE, Roman, LD, Phase II trial of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol 27 (2009), 1069–1074.
Garcia, AA, Blessing, JA, Vaccarello, L, Roman, LD, Phase II clinical trial of docetaxel in refractory squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. Am J Clin Oncol 30 (2007), 428–431.
Lorusso, D, Ferrandina, G, Pignata, S, et al. Evaluation of pemetrexed (Alimta, LY231514) as second-line chemotherapy in persistent or recurrent carcinoma of the cervix: the CERVIX 1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) Group. Ann Oncol 21 (2010), 61–66.
Miller, DS, Blessing, JA, Bodurka, DC, Bonebrake, AJ, Schorge, JO, Evaluation of pemetrexed (Alimta, LY231514) as second line chemotherapy in persistent or recurrent carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group. Gynecol Oncol 110 (2008), 65–70.
Boussios, S, Seraj, E, Zarkavelis, G, et al. Management of patients with recurrent/advanced cervical cancer beyond first line platinum regimens: where do we stand? A literature review. Crit Rev Oncol Hematol 108 (2016), 164–174.
Chung, HC, Ros, W, Delord, JP, et al. Efficacy and safety of pembrolizumab in previously treated advanced cervical cancer: results from the phase II KEYNOTE-158 study. J Clin Oncol 37 (2019), 1470–1478.
National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology. Cervical cancer. Version 1. https://www.nccn.org/professionals/physician_gls/pdf/cervical.pdf, 2020. (Accessed 21 April 2020)
Förster, Y, Meye, A, Albrecht, S, Schwenzer, B, Tissue factor and tumor: clinical and laboratory aspects. Clin Chim Acta 364 (2006), 12–21.
Pan, L, Yu, Y, Yu, M, et al. Expression of flTF and asTF splice variants in various cell strains and tissues. Mol Med Rep 19 (2019), 2077–2086.
Cocco, E, Varughese, J, Buza, N, et al. Expression of tissue factor in adenocarcinoma and squamous cell carcinoma of the uterine cervix: implications for immunotherapy with hI-con1, a factor VII-IgGFc chimeric protein targeting tissue factor. BMC Cancer, 11, 2011, 263.
Zhao, X, Cheng, C, Gou, J, et al. Expression of tissue factor in human cervical carcinoma tissue. Exp Ther Med 16 (2018), 4075–4081.
de Goeij, BE, Satijn, D, Freitag, CM, et al. High turnover of tissue factor enables efficient intracellular delivery of antibody-drug conjugates. Mol Cancer Ther 14 (2015), 1130–1140.
Breij, EC, de Goeij, BE, Verploegen, S, et al. An antibody-drug conjugate that targets tissue factor exhibits potent therapeutic activity against a broad range of solid tumors. Cancer Res 74 (2014), 1214–1226.
Alley SC, Harris JR, Cao A, et al. Tisotumab vedotin induces anti-tumor activity through MMAE-mediated, Fc-mediated, and Fab-mediated effector functions in vitro. AACR Annual Meeting 2019; Atlanta, GA; March 29–April 3, 2019 (abstr 221).
Eisenhauer, EA, Therasse, P, Bogaerts, J, et al. New Response Evaluation Criteria in Solid Tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45 (2009), 228–247.
Vergote, I, Coleman, RL, Pignata, S, et al. Joint ENGOT and GOG Foundation requirements for trials with industry partners. Gynecol Oncol 154 (2019), 255–258.
de Bono, JS, Concin, N, Hong, DS, et al. First-in-human study of tisotumab vedotin in advanced and/or metastatic solid tumours: a multicentre, phase 1/2 trial. Lancet Oncol 20 (2019), 383–393.
Hong, DS, Concin, N, Vergote, I, et al. Tisotumab vedotin in previously treated recurrent or metastatic cervical cancer. Clin Cancer Res 26 (2020), 1220–1228.
Muggia, FM, Blessing, JA, Method, M, et al. Evaluation of vinorelbine in persistent or recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. Gynecol Oncol 92 (2004), 639–643.
Schilder, RJ, Blessing, J, Cohn, DE, Evaluation of gemcitabine in previously treated patients with non-squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group. Gynecol Oncol 96 (2005), 103–107.
Lan, C, Shen, J, Wang, Y, et al. Camrelizumab plus apatinib in patients with advanced cervical cancer (CLAP): a multicenter, open-label, single-arm, phase II Trial. J Clin Oncol 38 (2020), 4095–4106.
Weiss, GR, Green, S, Hannigan, EV, et al. A phase II trial of carboplatin for recurrent or metastatic squamous carcinoma of the uterine cervix: a Southwest Oncology Group study. Gynecol Oncol 39 (1990), 332–336.
Prince, HM, Kim, YH, Horwitz, SM, et al. Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial. Lancet 390 (2017), 555–566.
Bendell, J, Saleh, M, Rose, AA, et al. Phase I/II study of the antibody-drug conjugate glembatumumab vedotin in patients with locally advanced or metastatic breast cancer. J Clin Oncol 32 (2014), 3619–3625.
